☆ 4.3 Editorial Material

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

EXPERT OPINION ON DRUG SAFETY (2022)

Journal

EXPERT OPINION ON DRUG SAFETY

Volume 21, Issue 12, Pages 1441-1443

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.1080/14740338.2022.2160445

Keywords

romosozumab; osteoporosis; cardiovascular disease

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.